Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antihypertensive compounds with combined actions.

K H Rahn1

  • 1Department of Internal Medicine, University of Limburg, Maastricht, The Netherlands.

Journal of Cardiovascular Pharmacology
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[New hypertension guidelines].

Deutsche medizinische Wochenschrift (1946)·2013
Same author

[Differential hypertensive therapy according to the guidelines].

Der Internist·2009
Same author

[Are beta blockers no longer the medicines of choice for the treatment of hypertension?].

MMW Fortschritte der Medizin·2007
Same author

[Treating essential hypertension. Are beta blockers still first choice?].

MMW Fortschritte der Medizin·2007
Same author

ESH-ESC guidelines for the management of hypertension.

Herz·2006
Same author

Arterial distensibility, intima media thickness and pulse wave velocity after renal transplantation and in dialysis normotensive patients.

International angiology : a journal of the International Union of Angiology·2005

Combining multiple antihypertensive drugs can be complex. Dual-action medications, like labetalol and carvedilol, offer a simpler approach to managing hypertension by combining different mechanisms in one pill.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Antihypertensive drug combinations are common but can lead to complex therapies.
  • Physiological counter-regulatory mechanisms can limit the effectiveness of single-agent therapy.
  • Developing single molecules with multiple mechanisms aims to simplify treatment and improve outcomes.

Purpose of the Study:

  • To review the development and application of dual-action antihypertensive drugs.
  • To discuss the therapeutic advantages and challenges of combining different pharmacological actions within a single molecule.

Main Methods:

  • Review of existing literature on dual-action antihypertensive agents.
  • Analysis of pharmacological profiles and clinical applications of specific drugs.
  • Comparison of efficacy and side effect profiles with traditional combination therapies.

Related Experiment Videos

Main Results:

  • Labetalol, combining alpha- and beta-receptor blockade, is established for acute and chronic hypertension management.
  • Carvedilol offers combined beta-blockade and vasodilation for blood pressure reduction.
  • Celiprolol is another agent with combined beta-1 and alpha-2 receptor blockade under investigation.

Conclusions:

  • Dual-action antihypertensive drugs offer a promising strategy to overcome limitations of combination therapy.
  • These agents may simplify treatment regimens and potentially improve patient adherence and outcomes.
  • Further clinical investigation is ongoing for newer dual-action compounds like carvedilol and celiprolol.